Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
NCT06068400Terminated
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Feb 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of BCMA/GPRC5D CAR-T in multiple myeloma (MM), sponsored by Guangzhou Bio-gene Technology Co., Ltd. Primary endpoints: Evaluation of Safety up to 2 years and Changes in cytokine level up to 2 years. Started Sep 2023; status: terminated.
02
Drugs
BCMA/GPRC5D CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06068400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06068400.